59MO Final analysis of AK105-302: A randomized, double-blind, placebo-controlled, phase III trial of penpulimab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC. (December 2022) - Han, B.; Jiao, S.; Chen, J.; Wang, Z.; Zhao, Y.; Zhang, G.; Chen, G.; Zhou, M.; Zhou, J.; Du, Y.; Wu, L.; Xu, Z.; et al.